Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection (Q44352717)

From Wikidata

Jump to navigation Jump to search

scientific article published in February 2003

Language	Label	Description	Also known as
English	Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection	scientific article published in February 2003

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Helicobacter pylori

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

W M Wong

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Q Gu

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

S K Lam

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

F M Y Fung

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

K C Lai

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

W H C Hu

6

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Y K Yee

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

C K Chan

8

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

H H X Xia

9

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

M F Yuen

10

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

B C Y Wong

11

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

language of work or name

0 references

publication date

1 February 2003

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

553-560

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Cure of duodenal ulcer associated with eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

[High eradication rates in Helicobacter pylori infection in patients with duodenal ulcer who failed previous eradication therapy]

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Bismuth-based quadruple therapy with bismuth subcitrate, metronidazole, tetracycline and omeprazole in the eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Review article: the pharmacology of rabeprazole

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Regular review: treatment of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Treatment of Helicobacter pylori: an overview

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus--negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

13C-urea breath test without a test meal is highly accurate for the detection of Helicobacter pylori infection in Chinese

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Identifiers

10.1046/J.1365-2036.2003.01459.X

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44352717&oldid=2019691102"